1. Home
  2. Category
  3. Symptoms/Side Effects

Oncologic Emergencies

Advanced Print Exclusive

Clostridium Difficile: Reducing Infections Using an Evidence-Based Practice Initiative

Carol Nielsen
Rocio Sanchez-Vargas
April Perez
CJON 2019, A1-A6 DOI:
Background: Nosocomial Clostridium difficile ( C. difficile ) infections are adverse incidents that affect immunocompromised hospitalized patients. High-touch surface areas within the patient’s environment are frequently overlooked and are a source of microscopic bacterial transmission. Objectives...
0
No votes yet
Read this Article
Clinical Challenges

Hand-Foot Syndrome

Karen Pike
ONF 2001, 1519-1520 DOI:
Ms. K is a 41-year-old female with recurrent ovarian carcinoma. She was diagnosed four years ago with stage III endometrioid carcinoma of the left ovary, underwent reductive surgery, and completed six cycles of cisplatin and paclitaxel. She finished her therapy uneventfully and underwent a negative...
0
No votes yet
Read this Article
Article

Hyperglycemia and Cancer: A State-of-the-Science Review

Marilyn Hammer
Susan Storey
Denise Soltow Hershey
Veronica J. Brady
Ellen Davis
Natalie Mandolfo
Ashley Leak Bryant
Jill Olausson
ONF 2019, 46(4), 459-472 DOI: 10.1188/19.ONF.459-472
Problem Identification: Hyperglycemia can increase the risk for adverse events and outcomes in patients undergoing treatment for cancer. The purposes of this state-of-the-science review were to explore the complexity of hyperglycemia in patients with cancer and to analyze physiologic mechanisms and...
5
Average: 5 (1 vote)
Read this Article
CNE Article

Associated Toxicities: Assessment and Management Related to CAR T-Cell Therapy

Karen Anderson
Theresa Latchford
CJON 2019, 23(2), 13-19 DOI: 10.1188/19.CJON.S1.13-19
Background: The impressive disease response observed with chimeric antigen receptor (CAR) T-cell therapy is accompanied by the potential for unique and severe toxicities. Cytokine release syndrome (CRS) and neurologic toxicities have emerged as prominent toxicities associated with this treatment...
0
No votes yet
Read this Article
CNE Article
Online Exclusive Article

Chlorhexidine Gluconate Baths: Supporting Daily Use to Reduce Central Line–Associated Bloodstream Infections Affecting Immunocompromised Patients

Gladys N. Jusino-Leon
Linda Matheson
Lydia Forsythe
CJON 2019, 23(2), E32-E38 DOI: 10.1188/19.CJON.E32-E38
Background: Chlorhexidine gluconate (CHG) has a broad-spectrum antimicrobial property that has proven to be effective in prolonging skin antisepsis and decreasing pathogens often seen in oncology units. Objectives: The aim was to reduce the incidence of central line–associated bloodstream...
5
Average: 5 (2 votes)
Read this Article

Related e-Books

View More

Questions, Concerns or Requests

We're just a click away for assistance.